Home » Archives by category » Pharma Industry News
Alexion to acquire Achillion to strengthen rare diseases portfolio

Alexion to acquire Achillion to strengthen rare diseases portfolio

Alexion acquisition of Achillion : Alexion Pharmaceuticals has agreed to acquire rival US pharma company Achillion Pharmaceuticals for about $930 million in an all-cash deal as per the latest pharma acquisition news. Achillion is a clinical-stage biopharma company, which is engaged in developing oral small molecule Factor D inhibitors for the treatment of people with […]

Radioisotopes manufacturer SHINE Medical Technologies creates pharma unit

US radioisotopes manufacturer SHINE Medical Technologies has formed a new business division called SHINE Therapeutics in a move to boost its ability to focus on addressing critical future needs in the therapeutic isotope market. SHINE Therapeutics will focus initially on developing and commercializing lutetium‑177 or Lu‑177, which is a therapeutic isotope that is combined with […]

Continue reading …
CMAB Biopharma, BJ Bioscience join forces for bi-functional antibody BJ-005

CMAB Biopharma (Suzhou), a pure-play biologics CDMO, and BJ Bioscience have signed an agreement for the development and manufacturing of a bi-functional antibody called BJ-005 as the first initiative in an exclusive collaboration. As per the terms of the agreement, CMAB will offer a complete range of CMC research and manufacturing services that address the […]

Continue reading …
Boehringer Ingelheim expands pets vaccines production facility in Athens

German pharma giant Boehringer Ingelheim has wrapped up the $76 million expansion of its pets vaccines production facility at Athens in Georgia, US. The investment doubles the capacity of Boehringer Ingelheim to produce vaccines for pets in the US and across the world two times. Expansion of the pets vaccines production plant was announced in […]

Continue reading …
Icosavax, a new vaccine development company, launched in Seattle

Icosavax, a new pharma company, focused on developing vaccines against infectious diseases, has been launched in Seattle, Washington. The vaccine development company is backed by $51 million capital raised through a Series A financing round led by Qiming Venture Partners USA. Other investors in Icosavax are Sanofi Ventures, Adams Street Partners, and NanoDimension, alongside continuing […]

Continue reading …
Elicio raises $33m to advance lymph node-targeted immuno-therapies

US immuno-oncology company Elicio Therapeutics has raised $33 million through a Series B financing round to advance ELI-002, an Amphiphile mKRAS vaccine (AMP KRAS), and other lymph node targeted immuno-therapies. Elicio Therapeutics said that it has established an international investor base which includes Clal Biotechnology Industries, Efung Capital, and Livzon Pharmaceutical Group. According to the […]

Continue reading …
Sobi to acquire US pharma company Dova Pharmaceuticals in $915m deal

Sobi acquisition of Dova Pharmaceuticals : Swedish Orphan Biovitrum (Sobi) has signed a deal worth up to $915 million to acquire Dova Pharmaceuticals, a US pharma company, in a move to become a major player in hematology and orphan diseases and also for expanding its footprint in the US. Shareholders of Dova Pharmaceuticals will be […]

Continue reading …
Currax Pharmaceuticals acquires Nalpropion Pharmaceuticals

Currax Pharmaceuticals, a specialty biopharma company having branded and generic drug businesses, has acquired Nalpropion Pharmaceuticals for an undisclosed price, as per the latest pharma acquisition news. Through the acquisition, Currax gains the global rights to CONTRAVE (naltrexone HCl and bupropion HCl extended release), a prescribed weight-loss drug in the US, which has patent protection till […]

Continue reading …
Meissa Vaccines raises $30m to move RSV Vaccine into clinical trials

Meissa Vaccines, a US biotech company focused on developing vaccines for the prevention of viral respiratory infections, has raised $30 million in a Series A financing with Morningside Ventures. The US biotech company plans to use the new capital for the expansion of its team, for undertaking phase 1 and 2 clinical trials for its […]

Continue reading …
Constellation doses first patient in phase 1 trial of CPI-0209 for cancer

Constellation Pharmaceuticals, a US clinical-stage biopharmaceutical company, has dosed the first patient in a Phase 1/2 clinical trial of CPI-0209, a second-generation EZH2 (enhancer of zeste homolog 2) inhibitor in cancer. The Phase 1 dose-escalation phase of the clinical trial will assess the efficacy of CPI-0209 monotherapy in advanced, relapsed solid tumor patients. With extended […]

Continue reading …
Page 1 of 17123Next ›Last »